Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza)

2019-10-15 11:11:28 | BioPortfolio


Prospective feasibility and validation study of a novel, near-to-care modality for diagnosis of malignancy among cancer suspects.


Prospective feasibility and validation study of a novel contrast microhalography (CEM) device for diagnosis of malignancy in Botswana. Consenting patients identified by their providers as requiring a fine needle aspirate (FNA) or percutaneous biopsy for assessment for possible lymphoma or breast cancer will undergo standard diagnostic procedure. Concurrently these patients will have additional FNA fluid tested using the portable novel nanosensor-based device (CEM). Diagnosis made from standard anatomic pathology, flow cytometry, and/or cytology will be compared with the diagnosis made using the CEM platform. Assessment of the feasibility and acceptability of the CEM platform will be performed. Assessment of training requirements for CEM platform will be completed.

Study Design


Breast Neoplasms


Contrast Microhalography (CEM)


Botswana Harvard AIDS Institute




Harvard School of Public Health

Results (where available)

View Results


Published on BioPortfolio: 2019-10-15T11:11:28-0400

Clinical Trials [3448 Associated Clinical Trials listed on BioPortfolio]

Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings

This pilot trial studies how well contrast enhanced mammography works in diagnosing patients with suspicious breast findings. Diagnostic procedures, such as contrast enhanced mammography, ...

The MONET - Study: MR Mammography of Nonpalpable Breast Tumors

The purpose of this study is to determine whether performing MRI of the breast will improve breast cancer management by reducing the number of biopsies and in case of malignancy allowing o...

Comparison of Three Methods for Early Detection of Breast Cancer

Subjects with suspicious breast lesion (BIRADS category 4/5) who are scheduled to undergo biopsy will be recruited to undergo imaging evaluation with Contrast Enhanced Dual Energy Mammogra...

High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)

This study is being performed to find out if a new kind of breast imaging (called contrast-media enhanced breast CT or CE-BCT) can help doctors to see the small structures in breast tissue...

Breast Cancer Screening With Diffusion-weighted MRI in Women at High Risk for Breast Cancer

A prospective observational multicenter study to compare the outcome of breast cancer surveillance using mammography, breast US, contrast-enhanced MRI, and diffusion-weighted MR imaging (D...

PubMed Articles [7018 Associated PubMed Articles listed on BioPortfolio]

Preliminary study: Breast cancers can be well seen on 3T breast MRI with a half-dose of gadobutrol.

Dynamic contrast enhanced (DCE) breast MRI is highly sensitive for breast cancer and requires gadolinium-based contrast agents (GBCA)s, which have potential safety concerns.

Elevated risk of radiotherapy-associated second malignant neoplasms in young African American women survivors of stage I-IIIA breast cancer.

To estimate the impact of radiotherapy (RT) on non-breast second malignant neoplasms (SMNs) in young women survivors of stage I-IIIA breast cancer.

Qualitative microwave imaging of breast cancer with contrast agents.

A microwave imaging (MWI) methodology for early diagnosis of breast
 cancer is presented. Instead of generating a tomographic image of the breast, the
 proposed technique aims to recon...

Commentary on: A Case Report of a Breast Implant-Associated Plasmacytoma and Literature Review of Non-ALCL Breast Implant-Associated Neoplasms.

Markerless pancreatic tumor target localization enabled by deep learning.

To estimate the impact of radiotherapy (RT) on non-breast second malignant neoplasms (SMNs) in young women survivors of stage I-IIIA breast cancer.

Medical and Biotech [MESH] Definitions

Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.

Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.

Neoplasms, usually carcinoma, located within the center of an organ or within small lobes, and in the case of the breast, intraductally. The emphasis of the name is on the location of the neoplastic tissue rather than on its histological type. Most cancers of this type are located in the breast.

Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.

Tumors or cancer of the human BREAST.

More From BioPortfolio on "Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza)"

Quick Search

Relevant Topic

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Searches Linking to this Trial